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Insights from the study of cancer resistance in animals have led to the discovery of novel 
anticancer pathways and opened new venues for cancer prevention and treatment. Sickle 
cells (SSRBCs) from subjects with homozygous sickle cell anemia (SCA) have been shown 
to target hypoxic tumor niches, induce diffuse vaso-occlusion, and potentiate a tumori-
cidal response in a heme- and oxidant-dependent manner. These findings spawned the 
hypothesis that SSRBCs and the vasculopathic microenvironment of subjects with SCA 
might be inimical to tumor outgrowth and thereby constitute a natural antitumor defense. 
We therefore implanted the B16F10 melanoma into humanized hemoglobin SS knockin 
mice which exhibit the hematologic and vasculopathic sequelae of human SCA. Over 
the 31-day observation period, hemoglobin SS mice showed no significant melanoma 
outgrowth. By contrast, 68–100% of melanomas implanted in background and hemo-
globin AA knockin control mice reached the tumor growth end point (p < 0.0001). SS 
knockin mice also exhibited established markers of underlying vasculopathy, e.g., chronic 
hemolysis (anemia, reticulocytosis) and vascular inflammation (leukocytosis) that differed 
significantly from all control groups. Genetic differences or normal AA gene knockin do 
not explain the impaired tumor outgrowth in SS knockin mice. These data point instead 
to the chronic pro-oxidative vasculopathic network in these mice as the predominant 
cause. In related studies, we demonstrate the ability of the sickle cell component of this 
system to function as a therapeutic vehicle in potentiating the oncolytic/vasculopathic 
effect of RNA reovirus. Sickle cells were shown to efficiently adsorb and transfer the 
virus to melanoma cells where it induced apoptosis even in the presence of anti-reovirus 
neutralizing antibodies. In vivo, SSRBCs along with their viral cargo rapidly targeted the 
tumor and initiated a tumoricidal response exceeding that of free virus and similarly loaded 
normal RBCs without toxicity. Collectively, these data unveil two hitherto unrecognized 
findings: hemoglobin SS knockin mice appear to present a natural barrier to melanoma 
tumorigenesis while SSRBCs demonstrate therapeutic function as a vehicle for enhancing 
the oncolytic effect of free reovirus against established melanoma.
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inTrODUcTiOn
Insights from the study of cancer resistance in animals and 
humans have led to the discovery of novel anticancer pathways 
and opened new venues for cancer prevention and treatment (1, 
2). Mammals, such as elephants, blind moles, and some feral 
murine strains, have evolved intricate mechanisms to eradi-
cate cancer. These include cell-cycle accelerated DNA repair, 
checkpoint blockade, programed cell death, and replicative 
senescence controlled by a network of tumor-suppressor genes 
and mediators such as p53, Rb, and IFN-β (1–5). In genetically 
deficient humans with an increased incidence of tumors, the 
major defects appear in DNA repair and proapoptotic pathways 
(6). Recently, subjects with deficiencies in growth hormone 
receptor and insulin-like growth factor have shown a reduced 
cancer mortality highlighting a role of pro-growth pathways, 
oxidative stress, and age-dependent genomic instability in 
human oncogenesis (7) in a study of cancer incidence in more 
than 16,000 patients with sickle cells anemia (SCA), melanoma 
was not listed (8). To date, the notion that SCA or an animal 
model thereof might constitute a natural barrier to melanoma 
tumorigenesis has not been explored or demonstrated.
Sickle cell anemia is a monogenic hemoglobinopathy 
wherein glutamic acid, the sixth amino acid in the β-globin 
chain, is  displaced by valine (9, 10). This results in hemoglobin 
polymerization and sickling morphology during hemoglobin 
desaturation. Clinically, the disease is characterized by chronic 
hemolysis, intermittent vaso-occlusive events, and organ injury 
(11, 12). Endothelial cells are chronically activated and injured 
after contact with sickle cells, sickle cell-derived heme, and 
inflammatory mediators (9–12). Contributing to the micro-
vascular injury and dysfunction are abundant reactive oxygen 
species (ROS) generated in the course of relentless ischemia–
reperfusion, chronic hemolysis, and vascular inflammation 
(13–21).
The Townes model of SCA in knockin mice faithfully repli-
cates the clinical sequalae of human homozygous SCA together 
with its pro-oxidative and thrombo-inflammatory microvascular 
features (22–25). Such mice exhibit a γ–βS globin configura-
tion wherein mouse β-globin genes are replaced with human 
γ- and βS-globin genes and mouse α-globin genes are replaced 
with human α-globin genes (26, 27). They also switch human 
 hemoglobins (HbF to HbS) at 3  weeks of age when they start 
to develop chronic hemolysis, severe anemia, and vascular 
 inflammation (28).
Sickle cells (SSRBCs) from patients with SCA possess 
an ability to target established tumors and together with 
exogenous pro-oxidants produce a tumoricidal response 
(29). Recent studies have drawn a striking parallel between 
the hypoxic, pro-oxidative, and chronically upregulated 
microvasculature in SCA and the activated neovasculature 
of solid tumors (11, 22, 29–31). In both vascular networks, 
intravital microscopy shows that SSRBCs adhere rapidly to 
upregulated endothelium and recruit leukocytes and platelets 
forming microcellular aggregates that lead to vaso-occlusion 
(10, 29, 32–39). SSRBC velocity in venules of transgenic sickle 
mice and solid tumors is reduced resulting in SS hemoglobin 
polymerization and autohemolysis with consequent release 
of intracellular heme. The latter is a powerful cell toxin that 
together with ROS appear to mediate endothelial injury 
(14–16, 29). The consequent microvascular ischemia in SCA 
produces tissue injury and painful crisis while in tumors it 
causes tumor cell necrosis (29).
Collectively, these data spawned the hypothesis that the pro-
oxidative and thrombo-inflammatory vascular microenviron-
ment of SCA might interdict melanoma neoangiogenesis and 
thereby constitute a natural antitumor defense against this tumor. 
We therefore elected to study the outgrowth of B16F10 melanoma 
in transgenic mice with SCA.
In related studies, we examine the ability of human sickle 
cell component of the system as a therapeutic to augment onco-
lysis by a vasculopathic RNA virus. Previously, SSRBCs have 
demonstrated increased adherence to endothelium infected by 
RNA viruses (40). Indeed, some RNA viruses are known to tar-
get tumor neovasculature, compromise blood flow, and cause 
significant vascular injury (41, 42). Reovirus, a non-enveloped 
double stranded RNA virus, infects endothelial cells via its 
junctional adhesion molecule-A (JAM-A) and provides a con-
duit for the virus into the bloodstream (43, 44). In tumor cells, 
reovirus replicates independently of the Ras-EGFR pathway 
and exerts selective oncolysis via defective antiviral PKR (45, 
46). While this agent is effective when delivered intratumorally 
alone or together with anti-PDI or chemotherapy, it has shown 
only modest ability to kill tumor when used systemically. 
This is largely due to binding by circulating blood cells and 
elimination by seroreactive neutralizing antibodies (47–51). 
By contrast, when the virus is adsorbed to the surface of the 
dendritic cells and T cells, it can be delivered to tumor niches 
in lymph nodes where it exhibits tumoricidal activity (52). In 
search of a cell carrier for systemic delivery of reovirus, we 
reasoned that sickle cells might be a viable candidate to protect 
reovirus from host defenses, target it to tumor and synergize 
with virus-induced tumor vascular injury. Indeed, sickle cells 
have been shown to carry and deliver cytotoxics into hypoxic 
4T1 carcinomas and release fourfold more drug cargo into the 
tumor milieu than similarly loaded normal RBCs and free drug 
(53). We therefore loaded sickle cells with reovirus and found 
that the virus spontaneously translocates to melanoma cells 
in vitro and induces a tumoricidal response in vitro and in vivo 
exceeding that of similarly loaded normal RBCs (nRBCs) and 
free virus.
resUlTs
B16F10 Melanoma Outgrowth is impaired 
in sickle cell Knockin Mice
We determined whether the B16F10 melanoma indigenous 
to C57Bl6 mice could grow after implantation into sickle cell 
knockin mice expressing human βS-globin genes and hemo-
globin AA knockin mice expressing human βA-globin genes. 
These mice exhibit a background consisting of C57Bl/6 and 
30% of 129 genes by QP analysis. For background controls, 
we deployed C57Bl/6 mice and also B6129SF1/J mice and 
B6129SF2/J, which express murine 129 genes along with B6 
FigUre 1 | comparison of the outgrowth rate of B16F10 melanoma in sickle cell knockin mice with background and aa knockin mice is shown. 
B16F10 melanoma outgrowth is inhibited significantly in sickle cell knockin mice compared to background and AA knockin controls (p < 0.0001).
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genes. Figure  1 shows that B16F10 melanoma grew robustly 
in C57Bl/6, B6129SF1/J mice, and B6129SF2/J mice with mean 
volumes of 1000 mm3 by days 16–18 after implantation. Tumor 
outgrowth to a mean of 1000 mm3 was also evident in the AA 
knockin mice by day 27. By contrast, melanoma outgrowth 
was impaired significantly in SS knockin mice relative to all 
controls (p < 0.0001).
Kaplan–Meier analysis of survival to the tumor growth end 
point (tumor volume of 750 mm3) similarly indicates that con-
trol groups reached median end points well before day 31 after 
implant, whereas in sickle knockin mice, none of the implanted 
tumors reached this end point during this period (p <  0.0001 
compared to all controls, Figure 2).
Figure  3 shows the percentage of tumors that exceeded 
250 mm3 in each group during the 31-day observation period. In 
sickle cell knockin mice, only 2 of 29 (6.9%) tumors grew beyond 
this baseline size compared to 100% of C57Bl/6 and B6129SF1/J 
mice (p = < 0.0001), 81.2% of B6129SF2/J mice (p < 0.0001), and 
68.7% of AA knockin mice (p < 0.0004). Notably, the two tumors 
in the sickle cell knockin group that grew above baseline did not 
reach the 750 mm3 growth end point during the 31-day observa-
tion period. Histopathologic examination of the melanomas in 
the latter two mice showed clusters of venules congested with 
SSRBCs, surrounding mononuclear cell infiltrate and adjacent 
tumor cell necrosis (Figure  4). These results demonstrate that 
the incidence of B16F10 tumorigenesis is significantly impaired 
in SS knockin mice relative to background and AA knockin 
controls.
hematologic evaluation of ss Knockin 
Mice and controls
We examined the notion that the pro-inflammatory and pro-
oxidative vascular environment of SS knockin mice could explain 
the impaired melanoma outgrowth in SS knockin mice. Major 
causative factors of such pro-oxidative microvascular milieu in 
SS knockin mice are unrelenting ischemia–reperfusion, chronic 
hemolysis, and vascular inflammation (46, 47). In these mice, ane-
mia and reticulocytosis are established biomarkers of underlying 
chronic hemolysis, while leukocytosis is an indicator of sustained 
vascular inflammation (48, 49). We therefore compared reticulo-
cyte, leukocyte, and hemoglobin levels of SS knockin mice with 
all controls. Results shown in Table 1 indicate that the degree of 
reticulocytosis and leukocytosis in hemoglobin SS knockin mice 
was significantly different from all control mice (p < 0.00001 and 
p < 0.0001, respectively). Likewise, SS knockin mice were signifi-
cantly more anemic than all controls (p < 0.0001). These results 
indicate that unlike controls, SS knockin mice exhibit severe 
anemia, exaggerated reticulocyte and leukocyte counts consistent 
with their underlying chronic hemolysis, pro-inflammatory and 
pro-oxidative vasculopathy.
sickle cells adsorb and Transfer 
Oncolytic reovirus Vector to 
Melanoma cells In Vitro and In Vivo
Reovirus is known to be oncolytic, but its delivery to tumor 
cells  is interdicted by immune defenses and neutralizing 
TaBle 1 | comparison of biomarkers of chronic hemolysis and 
vasculopathic inflammation in ss Knockin mice and controls.a
ss aa c57Bl/6
Hct 28.3 ± 4.4 (n = 13) 41.6 ± 2.3 (n = 6) 42.4 ± 5.8 (n = 15)
Hgb 5.9 ± 1.1 (n = 14) 13.0 ± 0.9 (n = 20 14.2 ± 3.0 (n = 15)
Reticulocytes 73.2 ± 6.7 (n = 14) 11.4 ± 6.9 (n = 20) 5.4 ± 1.2 (n = 13)
WBCs 31.7 ± 4.6 (n = 14) 14.6 ± 4.6 (n = 20) 13.8 ± 6.3 (n = 14)
comparative statistics
hemoglobin reticulocytes WBcs
SS vs. AA p < 0.0001 p < 0.0001 p < 0.0007
SS vs. C57Bl-6 p < 0.0001 p < 0.0001 p < 0.0002
AA vs. C57Bl-6 ns ns ns
aData are given as the mean and SD.
“n” is the number of samples tested.
FigUre 4 | histopathologic section of melanoma implanted in sickle 
cell knockin mice that failed to show progressive growth is shown. H&E 
section of melanoma implanted into SS knockin mice is shown. Insert shows 
cluster of eleven venules congested with sickle cells (10× magnification). Higher 
power shows sickle cells occluding a venule with surrounding mononuclear cell 
infiltrate and adjacent tumor cell necrosis (40× magnification).
FigUre 3 | comparison of the percentage of B16F10 melanomas 
exhibiting growth to end point tumor volume within the 31-day 
observation period in ss knockin mice and background/allotypic 
hemoglobin controls is shown. B16F10 melanoma outgrowth is significantly 
impaired in SS knockin mice compared with C57Bl6, C57Bl61296F1, 
C57Bl6129F2 (**p < 0.0001), and AA knockin (*p = 0.0004) mice.
FigUre 2 | Kaplan–Meier analysis of sickle cell mice and controls is shown. Survival is significantly prolonged in the SS knockout mice compared to 
corresponding background controls and AA knockin mice. See text for details.
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antibodies (49–51). We therefore determined whether SSRBCs 
with their known tumor homing properties (29) could serve as 
vehicles for carriage and delivery of reovirus to tumor and pro-
tect it from neutralizing antibodies in vitro and in vivo. We first 
examined whether SSRBCs could bind reovirus and vesicular 
stomatitis virus (VSV) without replicating or inducing SSRBC 
cytotoxicity. Results shown in Figure 5 indicate that SSRBCs 
incubated with reovirus or VSV for 1  h at 37°C at various 
MOIs did not replicate or undergo cytotoxicity in a plaque 
forming assay. We then determined whether the viral-loaded 
SSRBCs could transfer reovirus and VSV to melanoma cells 
in the presence or absence of viral neutralizing antibodies. 
Results shown in Figure  6 demonstrate that when SSRBCs 
were loaded with reovirus (SSRBC-neo) and cocultured with 
B16tk melanoma cells, the virus translocated to melanoma 
cells and induced melanoma cell lysis at 24  h to a degree 
FigUre 5 | reovirus and vesicular stomatitis virus bind but do not replicate in ssrBcs. Reovirus and VSV do not replicate in and are not cytotoxic to 
SSRBC. Human SSRBC were plated in 96-well plates and were infected with various multiplicities of infection (MOI) with reovirus and VSV. At specific time points, 
an MTT assay was performed according to manufacturer’s instructions. Data are plotted as a percentage of control survival with SD.
FigUre 6 | reovirus is transferred to melanoma cells in vitro in the 
presence of neutralizing antibody. Shown above is B16tk melanoma 
cell lysis after co-incubation with SSRBCs that were loaded with reovirus 
(MOI = 1) for 2 h at 37°C, washed three times at a ratio of 1:1. In addition, 
at the time of coculture, reovirus neutralizing antibody was added to some 
of the wells. To demonstrate efficient removal of any unbound virus from 
the viral loaded SSRBC, an aliquot of the third wash was directly added to 
the B16tk cells. As a positive control, B16tk cells were directly infected 
with reovirus at an MOI of 1 with and without neutralizing antibodies. At 
specified time points, aliquots of the supernatant were collected and 
titered on L929 cells using a standard plaque forming unit assay. Data are 
plotted with SD.
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comparable to that of melanoma cells directly infected with 
virus in a standard plaque forming assay. The presence or 
absence of reovirus neutralizing antibody therefore did not 
abrogate the viral translocation from SSRBCs to melanoma 
cells and consequent melanoma cell lysis. VSV showed a 
similar ability to translocate from SSRBCs and infect mela-
noma cells (Figure 7). Results demonstrate that, even in the 
presence of neutralizing antibodies, SSRBCs efficiently adsorb 
and transfer reovirus and VSV to B16 melanoma cells resulting 
in tumor cell cytolysis.
ssrBcs localize in Melanoma and 
loaded with Oncolytic reovirus induce a 
Tumoricidal response
We compared the ability of intravenously administered SSRBCs 
and nRBCs to localize in melanomas. Results shown in Figure 8 
indicate that 30  min after injection SSRBCs accumulated in 
melanoma to a degree significantly greater than nRBCs. We then 
compared the ability of SSRBCs and nRBCs carrying oncolytic 
reovirus to induce a tumoricidal response in a B16 melanoma 
model. For this purpose, SSRBCs or nRBCs were loaded with 
reovirus as described in “Materials and Methods” and injected 
into mice bearing established B16 melanoma. As controls, mice 
were also injected with naked reovirus (5  ×  108 TCID50) or 
FigUre 8 | sickle cells accumulation in tumor compared to normal rBcs. Athymic nude mice were injected subcutaneously with 2 × 105 B16tk melanoma 
cells. When tumors were palpable, nRBCs or SSRBCs stained with Vybrant CmDiI (70% hematocrit) were injected intravenously. Thirty minutes after injection, 
tumors were harvested and converted to single cell suspensions. Still image of CmDIl uptake in representative tumor suspensions of nRBCs (a) and SSRBCs (B) 
from a tumor bearing mouse is shown. Image analysis of (a,B) shown in (c) indicates a greater number of CmDil staining SSRBCs than nRBCs (p < 0.001). FACS 
analysis of suspensions (D) confirmed the increased uptake of CmDil-staining SSRBCs relative to nRBCs in the melanomas (n = 3) (p < 0.05).
FigUre 7 | ssrBcs transfer vesicular stomatitis virus to melanoma cells. Human sickle RBC were incubated with or without VSV-GFP (MOI = 1) for 2 h at 
37°C, washed three times, and then cocultured with B16 cells stained with Vybrant CmDiI at a ratio of 1:1. At indicated time points the B16 cells were washed and 
analyzed by FACS. As a positive control, B16 cells were directly infected with VSV-GFP at an MOI of 1.
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PBS. Survival of mice receiving SSRBCs-reo was significantly 
prolonged compared to groups receiving nRBC-reo (p = 0.02), 
naked virus (p = 0.002), or PBS (p = 0.0003) (Figure 9). Mice 
showed no significant acute toxicity or weight loss during the 
study. These data demonstrate that reovirus-loaded SSRBCs 
can be delivered to melanoma in vivo and induce a tumoricidal 
response exceeding that of the nRBC-reo, PBS control and naked 
reovirus without significant acute toxicity.
FigUre 9 | ssrBcs loaded with reovirus significantly improve the 
survival of mice bearing established B16 melanoma. Athymic nude 
mice were subcutaneously injected in the flank with 2 × 105 B16ova cells. 
Once tumors were palpable, nRBC or SSRBC were loaded with reovirus for 
2 h at 37°C, washed three times and intravenously injected at a hematocrit 
of 70%. As controls, mice were also intravenously injected with PBS or 
reovirus (5 × 108 TCID50). Naked reovirus and reo-nRBC prolonged the 
survival of B16ova-bearing mice compared to the PBS control (p = 0.0434 
for reovirus alone; p = 0.0213 for reo-nRBC). However, reo-SSRBC 
achieved a highly significant survival enhancement compared to the other 
three treatment groups (PBS, p = 0.0003; naked reovirus, p = 0.0020; 
reo-nRBC, p = 0.020).
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DiscUssiOn
Here, we show that melanoma outgrowth is impaired significantly 
in transgenic SS knockin mice relative to C57BL/6, B6129SF1/J, 
and B6129SF2/J background controls and transgenic hemoglobin 
AA mice. The B16F10 melanoma is syngeneic in C57BL/6 mice 
but grows comparably in B6129SF1/J and B6129SF2/J mice, 
which express 129 genes together with B6 genes. This suggests 
that the 129 genetic component did not interfere significantly 
with melanoma outgrowth. Likewise, SS and AA mice not only 
express 129 and B6 genes but also synthesize human hemoglobin 
allele(s). Since tumor outgrowth occurred in a significantly 
higher percentage of hemoglobin AA mice relative to SS mice, the 
presence of the human hemoglobin AA alleles did not appear to 
interfere significantly with tumor outgrowth or tumor incidence. 
The restricted tumor outgrowth in SS mice can therefore be 
explained by the presence of hemoglobin SS alleles in SS knockin 
rather than by genetic differences between the strains.
As shown herein, impaired melanoma outgrowth in sickle 
cell knockin mice was accompanied by significant anemia, 
reticulocytosis, and leukocytosis relative to controls. In sickle 
cell knockin mice, reticulocytosis is an established marker of 
underlying chronic hemolysis, while leukocytosis is indica-
tive of a chronic thrombo-inflammatory microvasculopathy 
induced by recruitment of neutrophils and monocytes to sites 
of vaso-occlusion (14, 48, 49). In these mice, hemolysis is a 
consequence of repeated episodes of oxidatively stressful sick-
ling/unsickling, spontaneous SS hemoglobin auto-oxidation, 
and recurrent episodes of ischemia–reperfusion injury (19, 52, 
53). The latter activates vascular pro-oxidant mitochondrial 
networks (19), while hemolytic by-products arginase and 
heme reduce bioavailability of antioxidant nitrous oxide (13). 
SS heme, also activates nuclear factor-kB (Nf-kB) leading to 
expression of endothelial adhesins VCAM-1, ICAM-1 that bind 
cognate ligands on SSRBCs leading to formation of cellular 
microaggregates, blood stasis, vaso-occlusion, and organ injury 
(54, 55). Figure 4 showing clusters of tumor venules occluded 
by SSRBCs with surrounding tumor cell necrosis depicts the late 
phase of tumor microvascular injury. Hemolysis and leukocy-
tosis in SS knockin mice, denoted herein by reticulocytosis and 
leukocytosis, therefore, play a central role in the biogenesis of 
the thrombo-inflammatory microvasculopathy. Such an abnor-
mal vascular microenvironment is the likely basis of melanoma 
growth inhibition in SS knockin mice.
In both SCA and sickle knockin mice, ROS generation results 
from unrelenting ischemia–reperfusion and nitrous oxide insuf-
ficiency. This leads to elaboration of microvascular pro-oxidants 
NADH, endothelial xanthine oxidase, and peroxynitrites 
(16,  54). Excessive mitochondrial ROS generated during rep-
erfusion depolarizes mitochondrial membranes (56–59) while 
microvascular ROS signaling leads to endothelial activation. 
Intravital microscopy of activated vascular networks in sickle 
cell mice and solid tumors perfused with SSRBCs shows that 
microvascular blood flow stagnates leading to vaso-occlusion 
and autohemolysis with consequent release of excessive ROS 
(10–12, 29). This self-perpetuating pro-oxidant network is a 
major determinant of the microvascular injury in SCA and the 
tumor endothelium (12, 19, 20, 29).
The notion that this highly pro-oxidative microvasculature in SS 
knockin mice is antithetical to neoangiogensis after implantation 
of the B16F10 melanoma is supported by recent studies showing 
that powerful pro-oxidants doxorubicin and zinc protoporphyrin 
potentiate the tumoricidal effect of SSRBC infusions against the 
drug resistant, triple negative 4T1 breast carcinoma (29). In addi-
tion, SSRBC pro-oxidant surrogates hemin and H2O2 were shown 
to induce tumor cell cytotoxicity in vitro suggesting that heme, 
ROS, and heme-nitrosyl complexes generated by interaction of 
trapped SSRBCs with tumor endothelium are capable of lysing 
adjacent tumor cells (29). Okuno et al. demonstrated that silenc-
ing of the endothelial cell antioxidant mATM gene produced 
a pro-oxidative microvasculature, which suppressed B16F10 
angiogenesis and significantly delayed tumor outgrowth (60). 
Furthermore, inhibition of GSH and thioredoxin antioxidant 
pathways or selective activation of the Akt pro- oxidant pathways 
led to synergistic tumor regression confirming the remarkable 
potency of excessive ROS when harnessed for tumor eradication 
(61, 62). In this context, melanoma cells, in particular, have shown 
an increased sensitivity to exogenous H2O2 relative to other solid 
tumor cells (63).
In light of these data, it is likely that melanoma angiogenesis 
is interrupted in the pro-oxidative vascular microenvironment 
of sickle knockin mice. During angiogenesis, embryonic tumor 
blood vessels rely on host endothelial cells to sprout and grow, 
promoted by VEGF and stabilized by interactions with the extra-
cellular matrix (64, 65). VEGF receptors are activated early in 
tumor neoangiogenesis and their expression and activation may 
be impaired in the pro-oxidative vascular milieu of the SS knockin 
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mice (64, 65). Indeed, Subtinib a biologic that competitively 
blocks VEGF receptors inhibited B16F10 melanoma outgrowth 
(66). Circulating SSRBCs are likely trapped in the network of 
sprouting tumor microvessels. Heme and ROS generated from 
such trapped/hemolyzed SSRBCs may promote free radical 
generation resulting in tumor endothelial injury, vaso-occlusion, 
and regression of neoangiogenesis. It is therefore plausible that 
melanoma neoangiogenesis requiring a coordinated interac-
tion between endothelial cells of SS knockin mice and B16F10 
melanoma cells is compromised in the pro-oxidative, thrombo-
inflammatory microvascular environment of SS knockin mice.
In related studies, we assessed the ability of SSRBCs to act as a 
therapeutic to carry and deliver oncolytic reovirus to tumors and 
induce a tumoricidal effect. Previously, we showed that SSRBCs 
could be loaded with and release fourfold more drug into hypoxic 
tumors than free drug or similarly loaded nRBCs (53). Some viral 
carriers have shown an ability to localize in tumors and induce a 
tumoricidal effect, while others are hampered by their tendency 
to sequester in liver, lungs, and reticuloendothelial system (42, 
67–69). Although a proportion of virus-loaded SSRBCs are also 
removed by non-tumor organs, we show here that a larger fraction 
homes to tumors and extends survival relative to nRBCs and free 
virus. SSRBCs therefore appear to direct the virus to the tumor 
where it induces a tumoricidal response.
We further show that reovirus loaded onto SSRBCs can 
spontaneously translocate to melanoma cells. This transfer may 
be explained in part by the presence on melanoma cells of high-
affinity sialic acid residues along with JAM-A receptors, which 
promote dissociation of reovirus from its low affinity receptor on 
SSRBCs (70–72). Notably, adherence of the reovirus to SSRBCs 
does not kill these cells whereas viral binding to melanoma cells 
after viral transfer results in melanoma cytolysis. Primary viral 
adhesion to melanoma cells is followed by a secondary higher 
affinity interaction between the sigma head of the virus and 
JAM-A receptors, which promotes virus internalization and 
melanoma cell apoptosis (73). That neutralizing antibodies did 
not displace the bound virus from the SSRBCs or the melanoma 
cells may likewise be ascribed to a higher affinity of the virus for 
SSRBCs or melanoma cells. Alternatively, the dominant reovirus 
sigma head epitope recognized by neutralizing antibodies may be 
sterically screened from recognition by the topology of the virus 
when bound to SSRBC receptors.
We previously reported that infusion of human SSRBCs along 
with pro-oxidants into mice bearing established 4T1 breast car-
cinomas resulted in a tumoricidal response without significant 
toxicity or histopathologic tissue injury (29). In this context 
sections of all organs including brains of the treated mice were 
devoid of inflammation, thrombosis, or necrosis. The lack of 
toxicity of SSRBC infusions in non-SS tumor bearing mice may 
be explained by the absence of a procoagulant and inflammatory 
vascular phenotype in non-tumor organs and repeated cycles of 
ischemia–reperfusion that predispose SS knockin mice and SCA 
patients to vaso-occlusion.
Since SSRBCs largely target hypoxic vasculature with upregu-
lated adhesion receptors, cancer patients with vascular diseases 
bearing an underlying chronic oxidative stress signature such as 
hypertension and atherosclerotic cardio- and cerebrovascular 
disease (74) might be at risk higher risk of SSRBC treatment. 
However, the risk in these settings may be no greater than that of 
many widely used cancer cytotoxics (e.g., doxorubicin), antian-
giogenic agents (e.g., bevacizumab), and biologics (e.g., IL-2), 
which are known to exacerbate the same vascular conditions. 
The risk assessment protocol for prospective patients receiving 
SSRBC treatment would be similar to that used for patients at 
risk of chemotherapy-associated venous thromboembolism. 
Particular attention would be directed to parameters predictive 
of an inflammatory and procoagulant phenotype such as chronic 
leukocytosis with increased monocytes and PMNs along with 
high levels of acute phase proteins and cytokines to include 
TNFα, IL1β, IL6, IL8, IFNγ, CRP, CCL3, CCL2, lactoferrin/
elastase, thrombin-anti-thrombin complexes (TAT), and D-dimer 
(75–80). With appropriate precautions, SSRBC infusions may 
therefore be useful against several human tumor types without 
undue toxicity.
In conclusion, these data provide two hitherto unrecognized 
properties of SSRBCs. First, SS knockin mice restrict melanoma 
outgrowth relative to background and beta globin controls 
suggesting that their pro-oxidative microenvironment may 
constitute a natural host defense system against this tumor. The 
dissection of this network is likely to lead to pharmacologic 
mimicry and therapeutic integration of the relevant pro-oxidant 
systems for prevention and treatment of melanoma. Second, we 
show that the SSRBC component of this system can function 
as a therapeutic in its ability to carry and transfer oncolytic 
reovirus to melanoma cells and induce a tumoricidal response 
against established melanoma in vivo. SSRBCs and the natural 
microvasculopathic environment of SCA therefore provide 
novel insight into a potent natural anticancer network and offer 
promising new tools that can be harnessed for prevention and 
treatment malignant melanoma.
MaTerials anD MeThODs
Mice
All animal procedures were approved by the UAB and Mayo 
Foundation Institutional Animal Care and Use Committees or 
the Animal Use Committees in compliance with the Guide for 
the Care and Use of Laboratory Animals. Male and female mice 
8–12  weeks of age weighing 19–26  g were used. Hemoglobin 
SS knockin mice (B6; 129-Hbatm1(HBA/Tow) Hbbtm2(HBG1,HBB)/Tow/
Hbbtm3(HBG1,HBB)Tow/J) and homozygous hemoglobin AA knockin 
mice were obtained from a breeding colony maintained at UAB 
animal research facility. QTL evaluation of SS and AA knockin 
mice indicated that they are predominantly B6 and exhibit up to 
30% of 129 genes. C57BL/6, B6129SF1/J, and B6129SF2/J mice 
were purchased from Jackson (Bar Harbor, Me). Female athymic 
homozygous nude mice (nu−/nu–), between 8–12  weeks of age 
weighing 19–26 g, were obtained from Charles River Laboratories 
(Wilmington, MA, USA) or Harlan Laboratories (Indianapolis, 
IN, USA). The mice were housed five animals per cage in a 12-h 
light–dark cycle with water, food ad libitum. All infusions were 
performed using the retro-orbital route or tail vein.
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Tumors, cells, and Viruses
The B16/F10 melanoma (CRL-6475) was obtained from 
ATCC, Manassas, VA, USA. B16ova murine melanoma cell 
line was grown in Dubelcco’s modified Eagle medium sup-
plemented with 10% FBS and 5 mg/mL of G418. B16ova cells 
were derived from the parental cells by transduction of a 
cDNA encoding chicken ovalbumin gene. B16tk cells were 
derived from B16 cells by transducing them with a cDNA 
encoding the herpes simplex virus thymidine kinase (tk) 
gene (81) and were grown in DMEM supplemented with 10% 
FBS and 1.25 μg/mL puromycin. All cell lines were monitored 
routinely and found to be free of mycoplasma infection. 
Reovirus Dearing Type 3 was provided by Oncolytics Biotech 
Inc. (Calgary, AB, Canada). Vesicular stomatitis virus (VSV) 
was generated as previously described (82). Virus titers were 
measured by a standard plaque assay on L929 cells for reovirus 
and BHK-21 cells for VSV.
Tumor Outgrowth and established Tumor 
studies
Mice were injected in the right flank with 1  ×  105 B16F10 
melanoma cells in volume of 50 μL containing 25 μL of Matrigel 
(Fisher Scientific). For the studies in mice bearing B16F10 mela-
noma, tumor volumes were measured with standard calipers and 
volumes were calculated as length × width2/2 where length is the 
long axis and width the short axis. Mice were monitored for toxic-
ity. During the 32 day observation period, a tumor was considered 
to show progressive growth only if its volume exceeded 250 mm3. 
The end point was a tumor volume of 750–1500 mm3.
With the approval by the Institutional Review Board of Mayo 
Foundation normal and sickle red blood cells were obtained from 
patients with homozygous SCA or normal healthy volunteers. 
Informed consent was obtained from each donor. For B16ova 
melanoma studies, subcutaneous (s.c.) tumors were established 
by injecting 2 × 105 or 5 × 105 B16ova melanoma cells into the 
flank of C57Bl/6 mice. SSRBC or nRBC infusion studies were 
started when s.c. tumors reached approximately 200  mm3. 
SSRBCs or nRBCs were loaded with reovirus for 2  h at 37°C, 
washed three times, and injected intravenously at a hematocrit 
of 70% in 100 μL. Control mice were injected with PBS or free 
reovirus (5 × 108 TCID50). Prior to injection, cell smears were 
stained with DiffQuick, examined under a light microscope, 
and photographed to ensure sickle cell or normal erythrocyte 
morphology. Tumors were measured twice a week with stand-
ard calipers, and mice were monitored for toxicity. Mice were 
euthanized if toxicity was evident or tumor burden exceeded 
1500 mm3.
Viral loading of ssrBcs and nrBcs
For the survival studies, human (nude mice) or murine (C57Bl/6 
mice) nRBC or SSRBC were loaded with reovirus for 2 h at 37°C, 
washed three times, and injected intravenously at a hematocrit 
of 70%. As controls, mice were also injected intravenously 
with PBS or reovirus (5 × 108 TCID50). Prior to injection, cell 
smears were stained with Diff-Quick and examined under a light 
microscope to ensure that sickle cell or normal RBC morphology 
was maintained.
Viral Transfer studies from ssrBcs to 
Melanoma cells In Vitro
Sickle cells (SSRBC) were incubated with reovirus (MOI =  1) 
for 2  h at 37°C, washed three times, and then cocultured with 
B16tk at a ratio of 1:1. In addition, during coculture of reovirus 
with SSRBC, neutralizing antibody was added to selected wells. 
In order to demonstrate efficient removal of any unbound virus 
from the loaded SSRBC, an aliquot of the third wash was directly 
added to the B16tk cells. Additionally, B16tk cells were directly 
infected with reovirus at an MOI of 1 for comparison of B16tk 
cells incubated with and without reovirus neutralizing antibody. 
At specified time points, aliquots of the supernatant were collected 
and assayed on L929 cells in a standard plaque forming unit assay.
MTT assay
MTT [3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide] assays were performed as follows: Target cells were 
plated in quadruplicate on 96-well plates and were infected with 
reovirus at various MOIs (ranging from 0.1 to 100). Cell viability 
was assessed at the indicated time points according to manufac-
turer’s protocol (Promega, Madison, WI, USA). Optical density 
was read at 570  nm using an enzyme-linked immunosorbent 
assay plate reader corrected for background.
Tumor Uptake studies
Athymic nude mice were injected subcutaneously with 2 × 105 
B16tk melanoma cells. When tumors were palpable, nRBCs or 
SSRBCs stained with Vybrant CmDiI (70% hematocrit) were 
injected intravenously. Thirty minutes after injection tumors 
were harvested and tumor cells were dissociated into single cell 
suspensions and photographed. Fluorescence intensity of still 
images was quantified using Adobe Photoshop CS2 software 
(Adobe Systems Inc., San Jose, CA, USA). Ten determinations of 
pixel intensity from four quadrants of the image were obtained 
and averaged to yield mean fluorescence intensity. The difference 
in uptake of the dissociated cells was confirmed by FACS analysis.
hematology
Reticulocyte, leukocyte, and hemoglobin determinations were 
carried out on tail vein or retro-orbital samples of mouse blood 
using a Heska HemaTrue analyzer (Loveland, CO, USA).
histology
Sections of tumors were stained with hematoxylin and eosin.
statistical analyses
For tumor outgrowth studies, tumor growth curves were ana-
lyzed and compared by the method of Kruskal Wallis. Survival 
curves were plotted according to the Kaplan–Meier method, 
and statistical significance between the different treatment 
groups was determined using the log-rank (Mantel–Cox) and 
Gehan–Breslow–Wilcoxon tests. For comparison of individual 
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data points, two-sided Student’s t-test was applied to determine 
statistical significance.
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